Dr Reddy s developing new treatment options for COVID-19, says MD
SECTIONS
Last Updated: May 23, 2021, 11:21 AM IST
Share
Synopsis We are motivated to serve patients in every possible way and with utmost urgency. This is reflected in the multiple collaborations we have entered to develop and commercialise a wide range of preventive and curative options for COVID treatment, Dr Reddy s Laboratories Co-Chairman & Managing Director G V Prasad said in an analyst call.
Agencies
The Hyderabad-based drug major has already launched Sputnik V vaccine while partnering various organisations, including the Defence Research and Development Organisation.
Drug major Dr Reddy s Laboratories is working on the development of new treatment options for COVID-19 patients which it aims to launch over the next few months while ensuring uninterrupted supplies of its existing range of products for the infectious disease in the market, according to a top company official. The Hyderabad-based drug maj
Dr Reddy s working on new treatment options for COVID-19, says MD yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.
India News: Drug major Dr Reddy's Laboratories is working on the development of new treatment options for Covid-19 patients which it aims to launch over the next
Results: Dr Reddy s profit declines 29% to Rs 557 crore in Q4
Pixabay
Dr Reddyâs Laboratories reported 29 percent year-on-year decline in net profit to Rs 557 crore for the fourth quarter ended in March 30, 2021.
The Hyderabad-based drug major had posted a net profit of Rs 781 crore in January-March period of 2019-20.
For 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20.
The drug maker reported 6.7 percent year-on-year growth in consolidated revenues to Rs 4,728 crore for the fourth quarter of the last financial year supported by India and Europe businesses.
Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in the fourth quarter of 2019-20, Dr Reddy s Laboratories said in a regulatory filing.